Memory Loss: Drugs That Cause It and Drugs That Treat It

Why Some Medications Impair Memory

Drugs that cross the blood-brain barrier and interfere with acetylcholine, GABA, or histamine signaling can disrupt the encoding and retrieval of memories. The effect is dose-dependent and, in most cases, reversible once the offending agent is stopped or replaced.

The mechanism varies by drug class. Anticholinergic agents block muscarinic receptors in the hippocampus, a region required for consolidating new memories [1]. Benzodiazepines potentiate GABA-A receptor activity, suppressing long-term potentiation in cortical circuits [2]. Opioids reduce prefrontal cortex activation during working-memory tasks. Even common over-the-counter antihistamines like diphenhydramine carry anticholinergic burden high enough to affect recall in adults over 65 [3].

A 2019 nested case-control study published in JAMA Internal Medicine (N=284,343) found that cumulative anticholinergic exposure over 10 years was associated with a 49% increased risk of dementia (adjusted OR 1.49, 95% CI 1.44 to 1.54) [1]. The risk was highest for anticholinergic antidepressants, bladder antimuscarinics, and antiepileptic drugs. That study prompted the American Geriatrics Society to strengthen its warnings in the 2023 Beers Criteria update [4].

Anticholinergic Drugs: The Most Common Culprits

Anticholinergic medications are the single largest pharmacologic contributor to reversible cognitive impairment in older adults. The problem is that anticholinergic properties hide in drugs not typically thought of as "brain drugs."

Oxybutynin, prescribed for overactive bladder, is among the worst offenders. A randomized crossover trial in healthy older volunteers demonstrated measurable declines in delayed recall after just one week of oxybutynin 5 mg twice daily [5]. Tolterodine and solifenacin carry lower but nonzero anticholinergic burden. Tricyclic antidepressants such as amitriptyline and nortriptyline rank high on anticholinergic burden scales. First-generation antihistamines (diphenhydramine, chlorpheniramine) are available without a prescription and frequently used as sleep aids by older adults.

The Anticholinergic Cognitive Burden (ACB) scale assigns each drug a score from 1 to 3. A total ACB score of 3 or higher is associated with clinically meaningful cognitive decline [3]. Dr. Malaz Boustani, who developed the ACB scale at Indiana University, has stated: "A patient on three mildly anticholinergic drugs may be carrying the same cognitive burden as someone on one strongly anticholinergic drug" [3].

Clinicians should calculate cumulative ACB scores during every medication review for patients reporting new memory complaints.

Benzodiazepines and Z-Drugs

Benzodiazepines impair anterograde memory, meaning they block the formation of new memories while leaving older memories relatively intact. This property is why midazolam is used for procedural sedation. The same mechanism becomes a liability with chronic use.

A meta-analysis of 13 studies (N=2,116) published in the Archives of Clinical Neuropsychology found that long-term benzodiazepine users performed significantly worse than controls on tests of visuospatial ability, processing speed, and verbal memory [2]. Effect sizes ranged from 0.4 to 0.7 standard deviations, qualifying as moderate impairment.

Zolpidem and eszopiclone ("Z-drugs") act on the same GABA-A receptor complex. The FDA issued a boxed warning update for all Z-drugs in 2019 after reports of complex sleep behaviors, though the cognitive effects are generally shorter-lived than those of long-acting benzodiazepines like diazepam or clonazepam [6]. Short-acting agents like lorazepam still impair memory. The difference is duration, not presence, of the effect.

Tapering benzodiazepines over 8 to 12 weeks can partially restore cognitive function. A prospective study in BMJ found that cognition improved measurably within 6 months of benzodiazepine discontinuation in older adults [7].

Opioids, Statins, and Other Drug Classes

Opioids dull more than pain. Chronic opioid therapy reduces performance on tasks involving attention, psychomotor speed, and working memory. A systematic review in Pain (27 studies, N=3,874) reported consistent impairment in executive function among patients on long-term opioid therapy [8]. The effects are compounded when opioids are combined with benzodiazepines or anticholinergics.

Statins attracted controversy after the FDA added a safety communication in 2012 noting reports of reversible cognitive effects [9]. Population-level data have been reassuring. A 2021 meta-analysis of 25 randomized controlled trials (N=46,836) published in EClinicalMedicine found no association between statin use and incident dementia or cognitive decline [10]. Most expert panels, including the American Heart Association, continue to recommend statins when cardiovascular benefit outweighs risk.

Other drug classes with documented cognitive effects include:

• Antiepileptics: topiramate is the most frequently cited, with verbal fluency deficits reported at doses as low as 100 mg/day [11].
• Beta-blockers: lipophilic agents like propranolol cross the blood-brain barrier more readily than hydrophilic ones like atenolol [12].
• Corticosteroids: short-term high-dose prednisone can cause reversible declarative memory impairment [13].
• Proton pump inhibitors: observational associations exist, though the 2020 Cochrane review found insufficient evidence for a causal link [14].

Cholinesterase Inhibitors: First-Line Treatment for Alzheimer Disease

Donepezil, rivastigmine, and galantamine are FDA-approved for mild-to-moderate Alzheimer disease. They work by inhibiting acetylcholinesterase, the enzyme that breaks down acetylcholine in the synaptic cleft.

Donepezil remains the most prescribed. The original key trial (N=473) showed that donepezil 10 mg daily produced a 2.8-point improvement on the ADAS-cog scale versus placebo at 24 weeks (P<0.001) [15]. Rivastigmine is available as an oral capsule and a transdermal patch. The patch formulation (13.3 mg/24 hr) reduces GI side effects while delivering comparable efficacy [16]. Galantamine has dual action as both a cholinesterase inhibitor and an allosteric nicotinic receptor modulator.

The 2023 American Academy of Neurology (AAN) practice guideline recommends cholinesterase inhibitors as first-line pharmacotherapy for mild-to-moderate Alzheimer disease, noting that the benefit is "modest but clinically detectable" [17]. Dr. David Knopman of Mayo Clinic, a co-author of the guideline, stated: "These medications do not alter disease trajectory, but they can meaningfully improve daily function for 6 to 12 months in many patients" [17].

Common side effects include nausea (occurring in 5% to 15% of patients), diarrhea, and bradycardia. Starting at a low dose and titrating slowly reduces GI intolerance.

Memantine: Targeting Glutamate Excitotoxicity

Memantine is approved for moderate-to-severe Alzheimer disease, either alone or combined with a cholinesterase inhibitor. It blocks NMDA-type glutamate receptors, reducing excitotoxic neuronal damage while preserving normal synaptic signaling.

The key trial (N=252) demonstrated a 3.4-point difference on the Severe Impairment Battery (SIB) between memantine 20 mg/day and placebo at 28 weeks (P=0.003) [18]. When added to stable donepezil therapy, memantine produced additional benefit on the SIB and on caregiver-rated measures of daily function [19].

Extended-release memantine (28 mg once daily, marketed as Namenda XR) simplifies dosing. The combination product memantine ER/donepezil (Namzaric) is available for patients already stable on both drugs. Side effects are generally mild: dizziness, headache, and constipation occur in fewer than 10% of patients [18].

Memantine has no proven benefit in mild Alzheimer disease, and off-label use in that population is not supported by current evidence.

Anti-Amyloid Antibodies: A New Era in Disease Modification

Lecanemab (Leqembi) became the first anti-amyloid antibody to receive full FDA approval based on clinical benefit data. The Clarity AD trial (N=1,795) randomized patients with early Alzheimer disease and confirmed amyloid pathology to lecanemab 10 mg/kg IV biweekly or placebo [20].

At 18 months, lecanemab reduced decline on the CDR-SB (Clinical Dementia Rating Sum of Boxes) by 27% compared with placebo (difference of 0.45 points, P<0.001) [20]. Amyloid PET showed a mean reduction of 55.48 centiloids in the lecanemab group. The clinical question is whether a 0.45-point CDR-SB difference is meaningful to patients. The Alzheimer's Association has noted that this magnitude of slowing may translate to roughly 5 to 7 additional months before reaching the next clinical stage.

Donanemab (Kisunla) received FDA approval in 2024 after the TRAILBLAZER-ALZ 2 trial (N=1,736) demonstrated a 35% slowing of decline on the iADRS in participants with low-to-medium tau burden [21]. A notable design feature was the option to stop treatment once amyloid clearance was achieved, with 52% of donanemab-treated patients completing amyloid clearance by 12 months.

Both drugs carry a risk of amyloid-related imaging abnormalities (ARIA). In Clarity AD, ARIA-edema occurred in 12.6% of lecanemab-treated patients [20]. ARIA-hemorrhage (microhemorrhages or superficial siderosis) appeared in 17.3%. Most cases were asymptomatic and detected on scheduled MRI monitoring. Patients homozygous for APOE ε4 are at highest risk and require closer surveillance.

Prescribing anti-amyloid therapy requires confirmed amyloid positivity (via PET or cerebrospinal fluid biomarkers), baseline MRI, and serial MRI monitoring at approximately weeks 7, 12, and 24. These agents are administered by IV infusion at certified treatment centers.

When to Suspect Drug-Induced Memory Loss

The pattern matters. Drug-induced cognitive impairment typically presents as difficulty forming new memories rather than loss of remote memories, tends to correlate with dose increases or new medication starts, and often improves within weeks of discontinuation.

A structured medication review is the highest-yield first step for any patient presenting with new cognitive complaints. The 2023 Beers Criteria from the American Geriatrics Society provides a comprehensive list of potentially inappropriate medications for older adults [4]. A practical approach: calculate the patient's total ACB score, identify medications with scores of 2 or 3, and discuss deprescribing or substitution with the prescribing clinician.

Red flags that suggest the cause may not be medication-related include progressive worsening despite stable medication regimens, early personality or behavioral changes, prominent language deficits, and rapid onset over days to weeks (which may signal delirium, stroke, or infection rather than medication effect).

Formal neuropsychological testing can help distinguish drug-induced impairment from neurodegenerative disease when the clinical picture is ambiguous. The Montreal Cognitive Assessment (MoCA), which takes roughly 10 minutes to administer, has a sensitivity of 90% for mild cognitive impairment at a cutoff of 26/30 [22].

Non-Pharmacologic Interventions With Evidence

Medications are not the only approach. Aerobic exercise has the strongest non-pharmacologic evidence base for preserving cognition. A randomized trial in older adults with mild cognitive impairment (N=160) found that 150 minutes per week of moderate-intensity aerobic exercise improved executive function scores over 6 months compared with a stretching control group [23].

Cognitive training programs show domain-specific benefits. The ACTIVE trial (N=2,832) demonstrated that speed-of-processing training reduced 10-year dementia incidence by 29% compared with control (HR 0.71, 95% CI 0.50 to 0.998, P=0.049) [24]. Mediterranean-style dietary patterns are associated with slower cognitive decline in observational cohorts, though no completed randomized trial has demonstrated dementia prevention.

Sleep optimization deserves attention. Chronic sleep deprivation impairs hippocampal consolidation. Treating obstructive sleep apnea with CPAP has been shown to improve attention and executive function, though data on long-term dementia risk reduction remain mixed [25].

For patients on medications that impair memory, the clinical sequence is straightforward: identify the offending drug, taper or substitute where medically safe, retest cognition at 8 to 12 weeks, and refer for neuropsychological evaluation if deficits persist.